Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

Fig. 3

a Mean change in cross-reactive ADA by visit using the MYL-1501D assay in INSTRIDE 1a and b actual median cross-reactive ADA by visit using the MYL-1501D assay in INSTRIDE 2.b ADA, antidrug antibodies; BL, baseline; %SB, percentage specific binding. aError bars represent the SD. bError bars represent the interquartile range

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us